Corporate Social Responsibility | Business Wire | PR NewsWire | Marketwire | Realwire | ACN/JCN newswire | 247pressrelease | PRWeb

HemoShear, LLC, Launches HepaShear Division

CHARLOTTESVILLE, Va. - 
      HemoShear, LLC, a developer of innovative, cell-based, human surrogate 
      models for discovery and assessment of new drug compounds in the 
      laboratory announces the formation of a new division, HepaShear, to 
      develop an advanced human surrogate model of the liver.
Posted : Mon, 09 Nov 2009 20:17:38 GMT
Author : HemoShear, LLC
Category : Press Release
News Alerts by Email ( click here )
Press Release News | Home
CHARLOTTESVILLE, Va. - (Business Wire) HemoShear, LLC, a developer of innovative, cell-based, human surrogate models for discovery and assessment of new drug compounds in the laboratory announces the formation of a new division, HepaShear, to develop an advanced human surrogate model of the liver.

“HepaShear will provide scientific expertise and a proprietary model to study liver diseases and accelerate discovery of innovative drug therapies in a novel system that closely mimics the biology and architecture of the human liver,” said Brett Blackman, Ph.D., Chief Scientific Officer of HemoShear.

Utilizing HemoShear’s proprietary technology, which applies human blood flow patterns to recreate the biology of organ tissue, HepaShear will vastly improve pharmaceutical scientists’ ability to identify new drug targets and discover compounds that have a greater likelihood of successful treatment of liver diseases in humans.

“Current methods do not adequately predict human biological responses to new drugs despite extensive testing in the laboratory and in animals. The HepaShear human surrogate model of the liver will be far more predictive of human responses and reduce risk of costly drug development failures,” said Brian Wamhoff, Ph.D., Vice President of R&D for HemoShear.

Wamhoff predicted the research would have profound effects. “I fully expect we will transform the way biomedical and pharmacological research will be conducted in the future by creating vastly improved models of liver function in order to study and treat liver diseases, such as hepatitis and cirrhosis, and improve drug efficacy for metabolic disorders such as diabetes and hypercholesterolemia, ” Wamhoff said.

The Company expects to complete development of the liver model and begin HepaShear’s commercial operations by late 2010.

About HemoShear, LLC

HemoShear’s proprietary technology recreates physiological function of human cells and tissue by applying human-derived blood flow forces to cultures of primary human vascular cells in the laboratory. HemoShear works in strategic partnerships with pharmaceutical companies to identify and validate pathways of disease progression, and to assess the efficacy and safety of new drug compounds. For information about HemoShear, please visit www.hemoshear.com.

HemoShear, LLC
Jim Powers, CEO (434) 872 0198


Copyright © 2008 Business Wire. All rights reserved.
Share/Save/Bookmark



Related News

GoldenSource Market Leadership Recognised in Financial News Tech21 List
LONDON, November 23 /PRNewswire/ -- GoldenSource has been recognised as a leading innovator in financial markets technology by Financial News in its 4th annual Tech 21 list of innovators and market leaders for the 21st century. GoldenSource wa...

Advanced ID Corp. Completes Repayment of La Jolla Cove Funding
CALGARY, AB -- 11/23/09 -- Advanced ID Corporation (OTCBB: AIDO) a leading developer of RFID solutions for supply chain applications, fleet operations, animal tracking and tire management announces today that it has fulfilled the terms of the Sept..

Research and Markets: 2009 Plimsoll Analysis - Abnormal Load Haulage - a Comprehensive Profile of 80 Companies Operating in the UK Market
DUBLIN - Research and Markets (

Aesthetic Plastic Surgery: The Next Generation Symposium Launches in NYC
NEW YORK - Aesthetic Plastic Surgery: The Next Generation Symposium will be held from December 4-6 at the Waldorf Astoria, announces Z. Paul Lorenc, MD, FACS, New York aesthetic plastic surgeon and Chairman of the APSSNY. The CME-accredited three-day interactive conference, h

MedPro Safety Products Reports Recent Progress
LEXINGTON, Ky. - MedPro Safety Products, Inc. (OTCBB: MPSP), a pioneer in the development and marketing of passive needlestick injury prevention technology, today reported on the Company’s recent progress. The recent highlights include:

Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain
NOVATO, Calif., Nov. 23 -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP) today announced the presentation of clinical trial data on NGX426, the Company's orally administered, non-opioid, AMPA/kainate receptor antagonist...

AngioDynamics to Participate in the 21st Annual Piper Jaffray Health Care Conference
QUEENSBURY, N.Y. - AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, announced today that it will present at the 21st Annual Piper Jaffray Health Care Conference in New York

Have your Say
Name
Email
Subject
Your Comment

Enter Verification code
 
  

 
Follow The Earth Times
Subscribe to RSS Follow Earth Times on TwitterNews by email
Share/Save/Bookmark
 
 



 
Subscribe to free Earthtimes
News Alerts by Email Click here
For RSS Feeds Click here
or Create your own RSS

Add to Google Toolbar
Breaking News
Press Releases

 


The Earth Times
News Category

© 2009 www.earthtimes.org, The Earth Times, All Rights Reserved | Privacy Policy
Earth Times accept no responsibility or liability either directly or indirectly for views or opinions expressed in articles or comments.